Healthcare Sector Announced Clinical Data Presentation, Upcoming Financial Release Schedules and Updates on New Drug

  Healthcare Sector Announced Clinical Data Presentation, Upcoming Financial
 Release Schedules and Updates on New Drug Applications - Research Report on
                 Alexion, Pacira, pSivida, Momenta and Impax

PR Newswire

NEW YORK, October 23, 2013

NEW YORK, October 23, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Alexion
Pharmaceuticals, Inc. (NASDAQ: ALXN), Pacira Pharmaceuticals Inc. (NASDAQ:
PCRX), pSivida Corp. (NASDAQ: PSDV), Momenta Pharmaceuticals Inc. (NASDAQ:
MNTA) and Impax Laboratories Inc. (NASDAQ: IPXL). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

Alexion Pharmaceuticals, Inc. Research Report

On October 16, 2013, Alexion Pharmaceuticals (Alexion) announced that its
researchers are scheduled to present data from clinical studies of Soliris
(eculizumab) in patients with atypical hemolytic uremic syndrome (aHUS), at
the annual meeting of the American Society of Nephrology (ASN), to be held
from November 5, 2013 to November 10, 2013, in Atlanta, Georgia. The Company
informed that that aHUS is a genetic, life-long, ultra-rare disease associated
with vital organ failure and premature death. Alexion stated that the
presentation will include: results from a prospective clinical trial of
Soliris in pediatric patients with aHUS, following the published results of a
retrospective study in pediatric patients with aHUS; results from an expanded
adult population, representing the largest prospective trial of Soliris in
adult patients with aHUS; and three-year follow-up data from two pivotal Phase
2 extension studies that highlight the long-term benefits of Soliris therapy
in patients with aHUS. The Full Research Report on Alexion Pharmaceuticals,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/4619_ALXN]

--

Pacira Pharmaceuticals Inc. Research Report

On October 17, 2013, Pacira Pharmaceuticals Inc. (Pacira) announced that it
will release its Q3 2013 financial results before the market opens on October
31, 2013. The Company stated that its management team will host a conference
call to discuss its financial results along with recent and upcoming
developments on the same day at 9:00 a.m. ET. The Company informed that a
live, listen-only webcast of the call will be available at the "Investors &
Media" section of the Company's website. Pacira added that the replay of the
call for two weeks, approximately two hours following the call will also be
accessible at the same location. The Full Research Report on Pacira
Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/c0aa_PCRX]

--

pSivida Corp. Research Report

On October 18, 2013, pSivida Corp. (pSivida) announced that its licensee
Alimera Sciences, Inc. has received a Complete Response Letter (CRL) for the
New Drug Application (NDA) for ILUVIEN from the U.S. Food and Drug
Administration (FDA). pSivida informed that the FDA stated that its NDA could
not be approved in its present form, due to concerns regarding the benefit to
risk and safety profiles of ILUVIEN. The Company informed that in order to
address the clinical and statistical deficiencies identified, FDA indicated
that results from a new clinical trial would need to be submitted, along with
at least 12 months of follow-up for all enrolled patients. Paul Ashton, PhD,
President and CEO of pSivida stated, "We are extremely disappointed by the
FDA's decision not to approve ILUVIEN at this time. However, we are pleased
that Alimera plans to continue to work with the FDA, through the advisory
committee, to determine whether there is a path forward in the U.S. for
ILUVIEN, and that Alimera believes it is well positioned for growth in Europe,
irrespective of the U.S. outcome, based on current traction in the countries
in which ILUVIEN has already been approved, coupled with the continued pursuit
of further country approvals." The Full Research Report on pSivida Corp. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/d4eb_PSDV]

--

Momenta Pharmaceuticals Inc. Research Report

On October 15, 2013, Momenta Pharmaceuticals Inc. (Momenta) announced that it
will release its Q3 2013 financial results on November 5, 2013 before the US
financial markets open. The Company informed that its management will host a
conference call on the same day at 10:00 a.m. EDT to discuss the results and
provide an update on the Company. Momenta added that a live webcast of the
call can be accessed through the "Investors" section of its website, and an
archived version of the webcast will be available on the website approximately
two hours following the call. The Full Research Report on Momenta
Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/c334_MNTA]

--

Impax Laboratories Inc. Research Report

On October 8, 2013, Impax Laboratories Inc. (Impax) announced that it will
release its Q3 2013 financial results on November 4, 2013, after the closing
of US financial markets. Impax informed that it will host a conference call
and live webcast on the same day at 4:30 p.m., ET. The Company stated that the
financial results and live webcast will be available through the Investor
Relations section of the Company's website. The Full Research Report on Impax
Laboratories Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/4c54_IPXL]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://AnalystsCorner.com



SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)